Deutsche Bank AG Reduces Position in Definitive Healthcare Corp. (NASDAQ:DH)

Deutsche Bank AG trimmed its position in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 84.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,578 shares of the company's stock after selling 176,204 shares during the quarter. Deutsche Bank AG's holdings in Definitive Healthcare were worth $138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. D. E. Shaw & Co. Inc. raised its holdings in Definitive Healthcare by 29.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 709,769 shares of the company's stock worth $2,917,000 after purchasing an additional 161,599 shares during the period. Bayesian Capital Management LP bought a new position in Definitive Healthcare in the 4th quarter worth $41,000. BNP Paribas Financial Markets bought a new position in Definitive Healthcare in the 4th quarter worth $313,000. Northern Trust Corp raised its holdings in Definitive Healthcare by 3.2% in the 4th quarter. Northern Trust Corp now owns 497,279 shares of the company's stock worth $2,044,000 after purchasing an additional 15,530 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Definitive Healthcare in the 4th quarter worth $1,181,000. 98.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Barclays cut their price target on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. BTIG Research lowered Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. Wall Street Zen lowered Definitive Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, May 31st. Finally, The Goldman Sachs Group raised their price objective on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research report on Monday, May 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $5.10.

Definitive Healthcare Trading Up 0.3%

DH traded up $0.01 on Thursday, hitting $3.56. The company had a trading volume of 497,933 shares, compared to its average volume of 811,850. The company has a market cap of $529.16 million, a PE ratio of -1.15, a PEG ratio of 4.06 and a beta of 1.58. Definitive Healthcare Corp. has a 12-month low of $2.15 and a 12-month high of $6.27. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The business's fifty day simple moving average is $2.89 and its 200 day simple moving average is $3.75.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $59.19 million during the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The firm's revenue was down 6.8% on a year-over-year basis. During the same quarter last year, the business posted $0.08 earnings per share. Equities research analysts expect that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.